US 8735553B1
· Li et al.
· 2014
[cited by applicant]
AU 2014201367A1
· 2014
[cited by applicant]
EP 3026062A1
· 2016
[cited by applicant]
WO WO2006121168A1
· 2006
[cited by applicant]
WO WO2008156712A1
· 2008
[cited by applicant]
WO 2010036959A2
· 2010
[cited by applicant]
WO WO2014206107A1
· 2014
[cited by applicant]
WO WO2015127407A1
· 2015
[cited by applicant]
WO WO2016106159
· 2016
[cited by applicant]
Abdiche, Y.N. et al., “Assessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platforms,” mAbs, vol. 8; No. 2; 264-277 (2016).
[cited by applicant]
Agata, Y. et al., “Expression of the PD-1 Antigen on the Surface of Simulated Mouse T and B Lymphocytes,” International Immunology, vol. 8; No. 5; 765-772 (1996).
[cited by applicant]
Boyd, S. D. et al., “Deep sequencing and human antibody repertoire analysis,” Current Opinion in Immunology, vol. 40; 103-109 (2016).
[cited by applicant]
Conroy, P.J. et al., “Antibodies: From novel repertoires to defining and refining the structure of biologically important targets,” Methods; vol. 116; 12-22 (2017).
[cited by applicant]
Damschroder, M.M. et al., “Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies,” Molecular Immunology, vol. 41; 985-1000 (2004).
[cited by applicant]
Ferrara, F. et al., “Recombinant renewable polyclonal antibodies,” mAbs, vol. 7; 32-41 (2015).
[cited by applicant]
Khan, L. et al., “Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library,” Scientific Reports, vol. 7; 45163; 12 p…
[cited by applicant]
Konitzer, J.D. et al., “Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor,” mAbs; vol. 9; No. 3; 536-549 (2017).
[cited by applicant]
Lee, J.L. et al., “Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenze vaccination,” Nature Medicine; vol. 22; 1456-1464 (2016).
[cited by applicant]
Parola, C. et al., “Integrating high-throughout screening and sequencing for monoclonal antibody discovery and engineering,” Immunology, vol. 153; 31-41 (2018).
[cited by applicant]
Sheehan, J. and Marasco, W.A., “Phage and Yeast Display,” Microbiology Spectrum, vol. 3; No. 1; 17 pages (2015).
[cited by applicant]
Van Regenmortel, M.H.V., “Development of a Preventive HIV Vaccine Requires Solving Inverse Problems Which is Unattainable by Rational Vaccine Design,” Frontiers in Immunology, vol. 8; 11 pages, (2018).
[cited by applicant]
Zhou, T. et al., “Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors,” Cell; 161; 1280-1292 (2015).
[cited by applicant]
Final Office Action for U.S. Appl. No. 15/152,192, mailed Jul. 9, 2019.
[cited by applicant]
Final Office Action for U.S. Appl. No. 16/728,653, mailed Nov. 3, 2022.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2015/066954, entitled: Anti-PD-1 Antibodies, mailed Jul. 6, 2017.
[cited by applicant]
Invitation to Pay Additional Fees with Partial Search Report for PCT/US2015/066954, entitled: “Anti-PD-1 Antibodies,” mailed Apr. 4, 2016.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 14/975,769, mailed Jul. 18, 2018.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/152,192, mailed Oct. 17, 2018.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/152,192, mailed Feb. 14, 2019.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/728,653, mailed Jul. 26, 2022.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 14/975,769, mailed Nov. 15, 2018.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/152,192, mailed Sep. 9, 2019.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/728,653, mailed Dec. 19, 2022.
[cited by applicant]
Transmittal of the International Search Report and the Written Opinion for International Application No. PCT/US2015/066954, entitled: “Anti-PD-1 Antibodies,” mailed May 30, 2016.
[cited by applicant]
Boyd, S.D. and Crowe, Jr., J.E., “Deep sequencing and human antibody repertoire analysis,” Current Opinion in Immunology, vol. 40; 103-109 (2016).
[cited by applicant]
Davies, J. and Riechmann, L., “Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding,” Immunotechnology, vol. 2; 169-179 (1996).
[cited by applicant]
Khan, L. et al., “Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library,” Sci. Rep.; vol. 7; 45163; 12 pages (201…
[cited by applicant]
Parola, C. et al., “Integrating high-throughput screening and sequencing for monoclonal antibody discovery and engineering,” Immunology, vol. 153; 31-41 (2018).
[cited by applicant]
Sheehan, J. and Marasco, W.A., “Phage and Yeast Display,” Microbiol. Spectr., vol. 3; No. 1; 17 pages (2015).
[cited by applicant]
Vaughan, T.J. et al., “Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library,” Nature Biotechnology, vol. 14; 309-314 (1996).
[cited by applicant]